Fludrocortisone acetate
Based on 2 publication(s) in Google Scholar
Fludrocortisone acetate (9α-Fludrocortisone acetate) is an orally active synthetic mineralocorticoid. Fludrocortisone acetate can effectively control sodium retention. Fludrocortisone acetate is used in studies of cardiac injury, adrenal insufficiency and orthostatic hypotension.
For research use only. We do not sell to patients.
- Purity: 99.59%
- CAS No.: 514-36-3
- Formula: C23H31FO6
- Molecular Weight:422.49
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Fludrocortisone acetate
More
Biological Activity
Fludrocortisone acetate is more effective than glucocorticoid Triamcinolone acetonide (HY-B0636) in restoring quiescent morphology and reducing membrane permeability in Phorbol-12-myristate-acetate (PMA)-stimulated choroidal endothelial cells (CECs)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Fludrocortisone acetate (0.05 mg/kg, p.o., twice daily, 4 consecutive days) results in a significant decrease in the UACR in healthy cats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 514-36-3
-
Appearance Solid
-
Molecular Weight 422.49
-
Formula C23H31FO6
-
Color White to off-white
-
SMILES
C[C@@]12[C@](C(COC(C)=O)=O)(O)CC[C@@]1([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3(F)[C@@H](O)C2)=O
-
Synonyms
9α-Fludrocortisone acetate; 9α-Fluorcortisol acetate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Coronavirus envelope protein activates TMED10-mediated unconventional secretion of inflammatory factors. [Abstract]2024 Oct 8;15(1):8708. PMID: 39379362 -
Solvent & Solubility
DMSO : 50 mg/mL (118.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.92 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.92 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Fitzgerald M, et al. Mineralocorticoids restore quiescent morphology and reduce VEGF receptor expression in inflamed choroidal endothelial cells in vitro. Ophthalmic Res. 2009;41(1):44-52. [Content Brief]
[2]. Sarker M, et al. Astaxanthin protects fludrocortisone acetate-induced cardiac injury by attenuating oxidative stress, fibrosis, and inflammation through TGF-β/Smad signaling pathway. Biomed Pharmacother. 2024 Dec;181:117703. [Content Brief]
[3]. Djajadiningrat-Laanen SC, et al. Urinary aldosterone to creatinine ratio in cats before and after suppression with salt or fludrocortisone acetate. J Vet Intern Med. 2008 Nov-Dec;22(6):1283-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3669 mL | 11.8346 mL | 23.6692 mL | 59.1730 mL |
| 5 mM | 0.4734 mL | 2.3669 mL | 4.7338 mL | 11.8346 mL | |
| 10 mM | 0.2367 mL | 1.1835 mL | 2.3669 mL | 5.9173 mL | |
| 15 mM | 0.1578 mL | 0.7890 mL | 1.5779 mL | 3.9449 mL | |
| 20 mM | 0.1183 mL | 0.5917 mL | 1.1835 mL | 2.9586 mL | |
| 25 mM | 0.0947 mL | 0.4734 mL | 0.9468 mL | 2.3669 mL | |
| 30 mM | 0.0789 mL | 0.3945 mL | 0.7890 mL | 1.9724 mL | |
| 40 mM | 0.0592 mL | 0.2959 mL | 0.5917 mL | 1.4793 mL | |
| 50 mM | 0.0473 mL | 0.2367 mL | 0.4734 mL | 1.1835 mL | |
| 60 mM | 0.0394 mL | 0.1972 mL | 0.3945 mL | 0.9862 mL | |
| 80 mM | 0.0296 mL | 0.1479 mL | 0.2959 mL | 0.7397 mL | |
| 100 mM | 0.0237 mL | 0.1183 mL | 0.2367 mL | 0.5917 mL |